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In the context of HIV infection, there is an increased
susceptibility to EBV- and KSHV-associated malignan-
cies. Evaluating a possible role for specific humoral
responses to individual viral proteins in the control of
viral load and prevention of EBV or KSHV related dis-
ease development in this population has been hampered
by the limited availability of suitable screening reagents.
We have developed a protein array platform that can be
utilized for EBV and KSHV serological screening. The
array consists of EBV and KSHV proteins printed onto
glass slides. All eighty-four EBV open reading frames and
eighty-six KSHV open reading frames were cloned into
bacterial vectors and the inserts validated by DNA sequen-
cing in both directions. Authenticated inserts were trans-
ferred to a yeast vector that expresses proteins as N-
terminal GST-fusions. Seventy-nine EBV proteins and
eighty-one KSHV proteins were successfully purified from
yeast. First-generation EBV/KSHV protein arrays have
been printed with these proteins plus a variety of control
proteins that include GST, and human IgG, IgM, and IgA.
Glycosylation of viral proteins may affect immuno-
genicity. To evaluate this aspect, EBV and KSHV virion
glycoproteins are being expressed in insect cells modi-
fied with the human glycosylation machinery. Once pur-
ified, these proteins will be added to the EBV/KSHV
protein arrays.
The ability to compare serological responses to the
complete repertoire of individual EBV and KSHV
encoded proteins should provide new insight into B cell
mediated immune regulation of these viruses.
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